Diabetes

Pre-IND meeting on diabetic peripheral neuropathy formulation announced

Published in Medical Letter on the CDC and FDA, May 2nd, 2004

The Quigley Corporation (QGLY) announced that Quigley Pharma completed its first meeting at the U.S. Food and Drug Administration (FDA) prior to submitting the company's Investigational New Drug (IND) application for its compound QR-333 for the relief of symptoms of diabetic symmetrical peripheral neuropathy.

The FDA's pre-IND meeting programs are designed to provide sponsors with advance, guidance, and input on drug development programs.

Richard Rosenbloom, MD, chief operating officer of Quigley Pharma Inc., stated, "Quigley Pharma received guidance from the FDA's Division of Anesthetic, Critical Care and Addiction Drug Products, on the next steps...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-05-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry